Compare BridgeBio Pharma Inc (BBIO) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs General Motors Company — how do they compare? BridgeBio Pharma Inc trades at $84.71 (market cap $16.46B), while General Motors Company trades at $76.69 (market cap $69.31B). The key difference: General Motors Company is far larger — about 4.2× BridgeBio Pharma Inc's market cap, and General Motors Company pays a 0.94% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GM | |
|---|---|---|
Market Cap | $16.46B | $69.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $86.38 |
52-Week Low | $44.81 | $48.89 |
Enterprise Value | $18.02B | $172.65B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
General Motors (GM) trades at $76.72, down 1.45% on the day, with a bearish technical signal from moving averages. The company shows strong cash flow from operations at $26.87B for 2025 and has beaten earnings estimates for three consecutive quarters. Recent news highlights GM's strategic pivot into energy and domestic manufacturing expansion, supported by a 63% analyst buy rating. Valuation metrics include a P/E of 28 and P/S of 0.4, indicating potential value relative to sales.
GM's outlook is mixed: solid cash generation and analyst optimism (consensus target $102) contrast with declining net margins (1.38% in 2025) and rising debt-to-asset ratios (46.79% in 2024). Risks include competitive pressures and macroeconomic headwinds, but the stock offers upside if margin improvements and energy initiatives materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
